Login
$VVOS
$0.08 +$0.00 (2.19%) After hours

$VVOS 8-K SEC Filings

Filed On Filing
21 Oct 2026 8-K: Other Events

Vivos Therapeutics Reports Nasdaq Confirmation of Compliance with Continued Listing Shareholders’ Equity Standard

19 Oct 2026 8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +5 more

This Assignment and Co-Ownership Agreement (this “Agreement”) is entered into as of the Closing Date under the Mutual Stock Purchase and Asset Exchange Agreement dated as of October 14, 2026 (as subsequently amended on October 15, 2026 a...

15 Oct 2026 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure +1 more

Certain exhibits and schedules to this Agreement have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Registrant agrees to furnish supplementally a copy of any omitted exhibit or schedule to the U.S. Securities and Exchang...

01 Oct 2026 8-K: Changes in Registrant's Certifying Accountant

We have read the statements made by Vivos Therapeutics, Inc. included under Item 4.01(a) of its Current Report on Form 8-K dated September 30, 2026 to be filed with the Securities and Exchange Commission. We agree with the statements con...

08 Sep 2026 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities

THE EXCHANGE CONTEMPLATED HEREIN IS INTENDED TO COMPORT WITH THE REQUIREMENTS OF SECTION 3(a)(9) OF THE SECURITIES ACT OF 1933, AS AMENDED.

21 Aug 2026 8-K: Regulation FD Disclosure

Vivos Therapeutics Opens New Sleep Testing and Treatment Facility in Nevada to Meet Rapidly Growing Patient Demand for Sleep Apnea Testing and Treatment

11 Aug 2026 8-K: Regulation FD Disclosure

Vivos Therapeutics Announces Issuance of New US Patent Broadening Protection for Its Vivos CARE Oral Medical Device Technology

03 Aug 2026 8-K: Entry into a Material Definitive Agreement; Departure/Election of Directors or Officers; Compensation

This Master Services Agreement (the “Agreement”) is entered into as of July 31, 2026 (the “Effective Date”) by and between The CFO Portal, LLC, a Florida limited liability company (“Provider”), and Vivos Therapeutics, Inc., a Delaware co...

07 Jul 2026 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more

This Securities Purchase Agreement (this “Agreement”) is dated as of June [_], 2026, between Vivos Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including i...

25 Jun 2026 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure

This letter agreement (this “Letter Agreement”) is entered into by and between Streeterville Capital, LLC, a Utah limited liability company (“Investor”), and Vivos Therapeutics, Inc., a Delaware corporation (“Company”), in connection wit...

16 Jun 2026 8-K: Other Events

Vivos Therapeutics Announces Intent to File a Registration Statement for a Proposed Rights Offering

16 Jun 2026 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure

This Collaboration Agreement (this “Agreement”) is entered into as of June 9, 2026 (the “Effective Date”), by and between Vivos Therapeutics, Inc., a Delaware corporation with principal offices at 7921 Southpark Plaza, Suite 210, Littlet...

08 Jun 2026 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +3 more

THE EXCHANGE CONTEMPLATED HEREIN IS INTENDED TO COMPORT WITH THE REQUIREMENTS OF SECTION 3(a)(9) OF THE SECURITIES ACT OF 1933, AS AMENDED.

22 Apr 2026 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule

On April 17, 2026, Vivos Therapeutics, Inc. (the “Company”) received a letter (“Letter”) from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company’s stockholders’ equity as ...

15 Apr 2026 8-K: Results of Operations and Financial Condition

Integration of The Sleep Center of Nevada and shift business model support path to improved revenues, margins and cash flow

03 Apr 2026 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities

This Securities Purchase Agreement (this “Agreement”) is dated as of March 31, 2026, between Vivos Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including i...

06 Feb 2026 8-K: Departure/Election of Directors or Officers; Compensation

Appointment of Gregg C. E. Johnson to the Board of Directors

20 Jan 2026 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities

NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UN...

16 Jan 2026 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more

THE SECURITIES REPRESENTED HEREBY HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER ANY STATE SECURITIES LAW. THE SECURITIES MAY NOT BE OFFERED, SOLD, OR OTH...

17 Dec 2025 8-K: Other Events

Vivos Eyes High Growth Potential from Commercial Affiliation with Prominent Auburn Hills, Michigan Sleep Practice MISleep Solutions

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support